Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands

Transfusion

Volumn 49, Issue 2, 2009, Pages 311-319

  Borkent Raven, B A ^a   Janssen, M P ^b   Van Der Poel, C L ^b   De Wit, G A ^b   Bonsel, G J ^b   Van Hout, B A ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD DONOR; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEPATITIS B; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; NETHERLANDS; NUCLEIC ACID AMPLIFICATION; PRESCHOOL CHILD; QUALITY OF LIFE; SCHOOL CHILD; SURVIVAL RATE; VIRUS TRANSMISSION;

BLOOD DONORS; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; DNA, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INCIDENCE; MARKOV CHAINS; MODELS, ECONOMIC; MODELS, STATISTICAL; NETHERLANDS; NUCLEIC ACID AMPLIFICATION TECHNIQUES;

EID: 58849162414     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01968.x     Document Type: Article

References (35)

1. AuBuchon JP. Emily Cooley Memorial Award. Managing change to improve transfusion safety. Transfusion 2004 44 : 1377 83.
2. Wilson K. The Krever Commission - 10 years later. CMAJ 2007 177 : 1387 9.
3. van der Poel CL, de Boer JE, Reesink HW, Sibinga CT Optimal versus maximal safety of the blood transfusion chain in The Netherlands; results of a conference. College for Blood Transfusion of the Dutch Red Cross Ned Tijdschr Geneeskd 1998 142 : 285 8.
4. Cuypers HT, van DR, Viret JF, Schottstedt V, Lankinen M, Da Silva Cardoso M, Lelie PN. European multi-centre validation study of NucliSens Extractor in combination with HCV Amplicor 2.0 assay for HCV-NAT screening of plasma pools. Biologicals 1999 27 : 303 14.
5. In vitro diagnostic medical devices. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices (1998-12-07 OJ No L 331/1). 2008. Available from: http://ec.europa.eu/ enterprise/newapproach/standardization/harmstds/reflist/invimedd.html
6. Koppelman MH, Assal A, Chudy M, Torres P, de Villaescusa RG, Reesink HW, Lelie PN, Cuypers HT. Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations. Transfusion 2005 45 : 1258 66.
7. Meltzer MI. Introduction to health economics for physicians. Lancet 2001 358 : 993 8.
8. Kleinman S. Residual risk of transfusion transmitted viral infections among seronegative donors: application of the incidence/window period model. Dev Biol Stand 2000 102 : 61 5.
9. Korelitz JJ, Busch MP, Kleinman SH, Williams AE, Gilcher RO, Ownby HE, Schreiber GB. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion 1997 37 : 634 40.
10. Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006 46 : 956 65.
11. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K Japanese Red Cross NAT Screening Research Group. HBV NAT positive [corrected] blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005 88 : 77 86.
12. de Wit G, Kretzschmar M, Smits L, Struijs J, Postma M, van de Laar M, Jager J. Kosten-effectiviteit van algemene vaccinatie tegen hepatitis B - (interimrapportage). RIVM rapport 403 505 004 2000.
13. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985 151 : 599 603.
14. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993 253 : 197 201.
15. Rodenburg-van Dieten H. Richtlijnen voor farmaco-economisch onderzoek; evaluatie en actualisatie. RIVM rapoort 24088606. 27-10-2005.
16. van Noord PA, van der Poel CL, van den Boom FM. Epidemiologisch onderzoek bij ontvangers van bloedproducten. Nederlands Tijdschrift voor de Geneeskunde 1997 141 : 1126.
17. Wallis JP, Wells AW, Matthews JN, Chapman CE. Long-term survival after blood transfusion: a population based study in the North of England. Transfusion 2004 44 : 1025 32.
18. Kleinman S, Marshall D, AuBuchon J, Patton M. Survival after transfusion as assessed in a large multistate US cohort. Transfusion 2004 44 : 386 90.
19. Gezondheidsraad. Algemene vaccinatie tegen hepatitis B. Den Haag : Gezondheidsraad 2001.
20. de Boer IM, op de Coul EL, Koedijk FD, van Veen MG, van de Laar MJ. HIV and sexually transmitted infections in the Netherlands in 2005. RIVM rapport 441100024/2006. 2006.
21. van der Bij AK, Coutinho RA, van der Poel CL. Surveillance of risk profiles among new and repeat blood donors with transfusion-transmissible infections from 1995 through 2003 in the Netherlands. Transfusion 2006 46 : 1729 36.
22. Statline, electronic database of statistics Netherlands. 6-10-2007. Available from: http://statline.cbs.nl/statweb/?la=en 2006.
23. van Hulst M, de Wolf JT, Staginnus U, Ruitenberg EJ, Postma MJ. Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002 83 : 146 55.
24. Custer B. Economic analyses of blood safety and transfusion medicine interventions: a systematic review. Transfus Med Rev 2004 18 : 127 43.
25. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995 15 : 369 90.
26. Reesink HW, Engelfriet CP, Henn G, Mayr WR, Delage G, Bernier F, Krusius T, Assal A, Gallian P, Corbi C, Morel P, David B, De Micco P, Murokawa H, Yugi H, Hino S, Tadokoro K, Flesland O, Brojer E, Letowska M, Olim G, Nascimento F, Gonçalves H, Castro L, Morais M, Stezinar SL, Alvarez M, Sauleda S, González R, Niederhauser C, Stolz M, Allain JP, Owusu-Ofori S, Eglin R, Stramer S, Busch M, Strong DM, Epstein J, Biswas R. Occult hepatitis B infection in blood donors. Vox Sang 2008 94 : 153 66.
27. Pereira A. Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union. Transfusion 2003 43 : 192 201.
28. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003 43 : 721 9.
29. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004 86 : 28 40.
30. Busch MP. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Transfus Clin Biol 2004 11 : 26 32.
31. Beutels Ph, Tormans G, Van Damme P, van Doorslaer E. Algemene vaccinatie tegen hepatitis B in Vlaanderen: kosten-effectief? Tijdschrift voor Sociale Gezondheidszorg 1996 74 : 272 81.
32. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003 52 : 425 32.
33. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, Krahn M. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003 98 : 630 8.
34. Tynell E, Norda R, Shanwell A, Björkman A. Long-term survival in transfusion recipients in Sweden, 1993. Transfusion 2001 41 : 251 5.
35. Kamper-Jorgensen M, Ahlgren M, Rostgaard K, Melbye M, Edgren G, Nyrén O, Reilly M, Norda R, Titlestad K, Tynell E, Hjalgrim H. Survival after blood transfusion. Transfusion 2008 Jul 30. [Epub ahead of print ].